Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-790052 with peginterferon alfa-2a and ribavirin in treatment-naive chronic hepatitis C genotype 2 or 3
2010-022408-28Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of daclatasvir, peginterferon alfa-2a and ribavirin in hepatitis C virus infection, sponsored by Bristol Myers Squibb. Primary endpoint: SVR24 by HCV genotype. Started Nov 2010; status: completed.
02
Drugs
daclatasvirpeginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-022408-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022408-28.